Literature DB >> 32109014

Leveraging vascular quality initiative data to improve hospital length of stay for patients undergoing endovascular aneurysm repair

Naomi Eisenberg1, Graham Roche-Nagle1, Thomas F. Lindsay1, George Oreopoulos1.   

Abstract

Background: The Society for Vascular Surgery Vascular Quality Initiative (SVS-SVQI) is a database that provides insight into standards of care and highlights opportunities for quality improvement by benchmarking institutional data against local, regional and national trends. Endovascular aneurysm repair (EVAR) is a frequently performed vascular operation. Postoperative length of stay in hospital (LOS) varies among institutions. We reviewed the morbidity and mortality of patients who underwent EVAR at our institution and the financial impact of increased LOS for these patients. In addition, we sought to identify modifiable factors associated with prolonged LOS.
Methods: We identified all patients who underwent elective EVAR between Jan. 1, 2011, and Dec. 31, 2014. Preoperative patient characteristics, intraoperative details, postoperative factors, long-term (1 yr) outcomes and cost data were reviewed. Univariate analysis was used to determine statistical differences between patients with LOS less than or equal to 2 days and greater than 2 days. Interventions were implemented to modify factors identified as having a negative impact on EVAR LOS.
Results: Identified factors that negatively affected EVAR LOS included social, neurologic, cardiovascular, urologic and renal issues. Following targeted interventions, LOS after EVAR decreased from an average of 3.8 to 3.0 days (p < 0.05). Logistic regression (n = 124) identified cardiovascular issues as the most significant predictor of LOS greater than 2 days (p = 0.001, odds ratio 14.24, 95% confidence interval 2.8–71.4). Reduction in LOS was associated with the additional benefit of 6.6% adjusted cost savings.
Conclusion: By leveraging SVS-VQI data, we were able to reduce EVAR LOS by identifying modifiable factors and instituting focused interventions. The reduction in LOS was associated with cost savings to the hospital.
© 2020 Joule Inc. or its licensors

Entities:  

Mesh:

Year:  2020        PMID: 32109014      PMCID: PMC7828953          DOI: 10.1503/cjs.003219

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  6 in total

1.  Potential clinical feasibility and financial impact of same-day discharge in patients undergoing endovascular aortic repair for elective infrarenal aortic aneurysm.

Authors:  Vincent P Moscato; Monica S O'Brien-Irr; Maciej L Dryjski; Hasan H Dosluoglu; Gregory S Cherr; Linda M Harris
Journal:  J Vasc Surg       Date:  2015-06-09       Impact factor: 4.268

2.  Targets to prevent prolonged length of stay after endovascular aortic repair.

Authors:  J Hunter Mehaffey; Damien J LaPar; Margret C Tracci; Kenneth J Cherry; John A Kern; Gilbert R Upchurch
Journal:  J Vasc Surg       Date:  2015-09-12       Impact factor: 4.268

3.  Selection, thirty day outcome and costs for short stay endovascular aortic aneurysm repair (SEVAR).

Authors:  N Al-Zuhir; J Wong; I Nammuni; G Curran; T Tang; K Varty
Journal:  Eur J Vasc Endovasc Surg       Date:  2012-03-26       Impact factor: 7.069

4.  Safety and feasibility of endovascular aortic aneurysm repair as day surgery.

Authors:  Stephen C Hanley; Oren Steinmetz; Eva S Mathieu; Daniel Obrand; Kent Mackenzie; Marc-Michel Corriveau; Cherrie Z Abraham; Heather L Gill
Journal:  J Vasc Surg       Date:  2018-02-01       Impact factor: 4.268

5.  Ambulatory percutaneous endovascular abdominal aortic aneurysm repair.

Authors:  Hasan H Dosluoglu; Purandath Lall; Raphael Blochle; Linda M Harris; Maciej L Dryjski
Journal:  J Vasc Surg       Date:  2013-08-24       Impact factor: 4.268

6.  Short Stay EVAR is Safe and Cost Effective.

Authors:  Sarah E Shaw; Ryan Preece; Katherine M Stenson; Jorg L De Bruin; Ian M Loftus; Peter J E Holt; Benjamin O Patterson
Journal:  Eur J Vasc Endovasc Surg       Date:  2018-11-12       Impact factor: 7.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.